Question-and-Answer Session
Operator
Thank you. (Operator Instructions). Our first question comes from the line Tim Anderson with Sanford Bernstein. Please go ahead.
Jay Olsen - Sanford Bernstein
Good morning, this is Jay Olsen for Tim Anderson. I have two questions. First, can you update us on what impact you might expect to see from generic Risperdal and Zyprexa in 2009? And secondly, can you tell us for Cymbalta how these sales break out between the depression indication and the fibromyalgia indication? Thank you.
John Lechleiter
[Tim] – let me take that. I have the answer to the question. While in terms of the impact of generic Risperdal, thus far, we haven't seen a demonstrable effect, in fact we continue to see some stabilization. We did see in the fourth quarter, a [rate of] decline in the Zyprexa volumes. I think it's still too early to tell, quite frankly in regards to if with the current economic pressures if payers will begin to drive greater generic contribution. In regards to your second question --
Ronika Pletcher
On the second part of the question, we've now started measuring both the fibro pain indication or fibro market and depression together. We no longer split the two. As of the last measure, we are about 6% of market. And that's up from a 5.7% initiation.
Nick Lumon
One of the things we do look at Jay is the prescriptions for Cymbalta compared to the prescriptions for Lyrica to at least see the general trends there. We continue to see that Cymbalta prescriptions grow at a faster rate than Lyrica. As you know, both of those have been weaker here in the fourth quarter than they had been in prior quarters of 2008.
Ronika Pletcher
[For comparison].
Nick Lumon
[I was going to say] on the same basis. If you look at with hematologists for fibromyalgia, we have captured about 25% of the new prescription share thus far. And that will be up from about 10% to 15%, not too long ago. Next caller, please.
Operator
Our next question comes from the line of Catherine Arnold with Credit Suisse. Please go ahead.
Catherine Arnold - Credit Suisse
Thanks John and good morning. I have two questions. One, I wanted to ask about the prasugrel panel and the TRILOGY study and was wondering, if you could give an update on TRILOGY's enrollment, and if you are going to be able to estimate any of the interim safety data for panel on FDA consideration of overall safety for the product, and particularly in the discussion of the 5-milligram dose? And, then I also wanted an update on your mGlu program. I think, at your analyst meeting you had said you have achieved data lock. So, I am wondering if we can look forward to the results of that buyer before the APA meeting and if you will also be presenting the [monkey tox] study. Thanks.
- To read the full transcript on Seeking Alpha, click here »
